Abstract
This study presents a retrospective analysis of 14,412 patients with acute respiratory infections (ARIs) in Ningbo, China, from January 2020 to December 2023. The research quantifies the dramatic resurgence of common respiratory pathogens following the complete relaxation of non-pharmaceutical interventions (NPIs) and the end of the dynamic zero-COVID policy. Key findings include a significant rise in overall pathogen activity, major outbreaks of Influenza A (IFV-A) and Mycoplasma pneumoniae (MP), a tripling of co-infection rates, and an expansion of susceptible age ranges, likely driven by a population-wide "immunity debt."
Introduction
For nearly three years, China’s strict NPIs—including universal masking, social distancing, and localized lockdowns—effectively suppressed the transmission of seasonal respiratory pathogens alongside SARS-CoV-2. While these measures were vital for public health during the pandemic, they also limited natural exposure, potentially leading to a "debt" of population-level immunity. This study aims to quantify the "rebound effect" observed after these measures were lifted in December 2022, providing critical insights for clinicians adjusting to the post-pandemic infectious landscape.
Methods
The researchers analyzed clinical data from 14,412 ARI patients at the Affiliated LiHuiLi Hospital of Ningbo University. The study period was divided into the NPI era (2020–2022, n=5,106) and the post-NPI era (2023, n=9,306). A comprehensive panel using PCR capillary electrophoresis detected ten common pathogens: Influenza A/B, Respiratory Syncytial Virus (RSV), Human Rhinovirus (HRV), Human Parainfluenza Virus (HPIV), Human Metapneumovirus (HMPV), Human Coronavirus (HCoV), Human Bocavirus (HBoV), Human Adenovirus (HAdV), and Mycoplasma pneumoniae (MP). Statistical tools included Joinpoint analysis for trend detection and Restricted Cubic Spline (RCS) models for age-risk assessment.
Results
Overall Trends in Pathogen Activity
Following the cessation of NPIs, Ningbo experienced a massive surge in respiratory infections. The monthly average positive rate for any pathogen rose from 43.05% during 2020–2022 to 68.46% in 2023. Joinpoint analysis confirmed a significant upward trend in pathogen activity starting in early 2023, marking a clear departure from the suppressed levels of the previous three years.
Pathogen-Specific Resurgence and Interference
The resurgence was not uniform across all pathogens. Influenza A (IFV-A) saw the most dramatic increase, with positivity skyrocketing from 1.59% to 22.14%. Similarly, Mycoplasma pneumoniae (MP) positivity rose from 4.07% to 19.18%, with an outbreak peaking in the summer and autumn of 2023 that surpassed pre-pandemic levels. Interestingly, the massive IFV-A outbreak appeared to "interrupt" the typical seasonal spread of RSV, suggesting competitive viral interference.
Shifting Demographics and Co-infections
The study observed a tripling of co-infection rates, jumping from 4.25% to 13.73% in 2023. The most common combination was HRV and MP. Furthermore, RCS models revealed that susceptible age ranges expanded for most pathogens. For IFV-A, the high-risk age range (Odds Ratio > 1) widened to include individuals aged 6 to 46, a significant expansion compared to the prior era.
Discussion and Limitations
The data strongly supports the hypothesis that the lack of exposure during the pandemic created an "immunity debt," leading to more aggressive outbreaks once NPIs were removed. However, the study has limitations: it is a single-center retrospective analysis from one hospital in Ningbo, which may not fully represent broader national trends. Additionally, the dataset only captures patients severe enough to seek hospital care, potentially missing milder community-level transmission.
Conclusion
The cessation of COVID-19 containment measures in China triggered a profound shift in the circulation of respiratory pathogens. The observed outbreaks of IFV-A and MP, alongside increased co-infections and widened demographic susceptibility, underscore the need for enhanced clinical vigilance and the establishment of robust, multicenter surveillance systems to manage future seasonal respiratory challenges.
Summary updated